好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Multiple Sclerosis (MS) Patients Taking Interferon-beta-1a (IFNb1a) Have Full Biological Activity in Both Stable and Breakthrough Disease
MS and Related Diseases
(-)
150
Authors/Disclosures
Susan E. Goelz, PhD (myelin repair foundation) No disclosure on file
Emmanuelle Waubant, MD, PhD, FAAN (USCF MS Center) The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.
Luca Bello (University of Padova, Department of Neuroscience NPSRR) Mr. Bello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Mr. Bello has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Edgewise Therapeutics. Mr. Bello has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Mr. Bello has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for PTC Therapeutics.
No disclosure on file
Mark Agius, MD (Barrow Neurological Institute Dept of Neurology) No disclosure on file
No disclosure on file
No disclosure on file